Efficacy and safety of roflumilast in Japanese patients older than 40 Years with chronic obstructive pulmonary disease (APTA-2217-06)
Study identifier:APTA-2217-06
ClinicalTrials.gov identifier:NCT00242294
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind comparative study)
Medical condition
Chronic obstructive pulmonary disease (COPD)
Phase
Phase 2/3
Healthy volunteers
None
Study drug
Roflumilast
Sex
All
Actual Enrollment
570
Study type
Interventional
Age
40 Years +
Date
Study Start Date: 01 Nov 2004
Primary Completion Date: 01 Sept 2006
Study Completion Date: 01 Mar 2007
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
TANABE SEIYAKU Co., LTD.
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
